AMD3100 further
reduces immune suppression by shifting characteristics of Tregs toward those of helper T cells, which would enhance antitumor effects.
Not exact matches
The VC - 01 product candidate is being developed as a potential long - term diabetes treatment with the goals of no
immune suppression required, and a
reduced risk of hypoglycemia and diabetes - related complications.
The VC - 01 product candidate is being developed as a potential long - term diabetes treatment with the goal of
reducing the risk of hypoglycemia and diabetes - related complications without requiring long - term
immune suppression.
This stress will actually
reduce the function of the
immune system - creating a vicious cycle of continued disease, continued inflammation, and continued
immune suppression.